01 Mar Agex Therapeutics Ceo Dr. Michael D. West To Present At Three Conferences In March 2018
March 01, 2018 08:00 AM Eastern Standard Time
ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX) today announced that the company’s Chief Executive Officer Michael D. West, Ph.D. will participate at three upcoming conferences: the Mauldin Economics Strategic Investment Conference, March 6-9 in San Diego; Undoing Aging, March 15-17 in Berlin, Germany; and the 10th World Congress and Expo on Cell & Stem Cell Research, March 19-21 in New York City.
“Induced tissue regeneration (iTR): Leveraging the unique regenerative potential of pluripotent stem cell-derived therapeutics.”
The Mauldin Economics Strategic Investment Conference
March 6-9 in San Diego, California
AgeX session: Wednesday, March 7, 1:50pm PST
Dr. West and AgeX’s VP of New Technology Discovery Aubrey de Grey, Ph.D. will participate on the Biotech panel, along with Eric Verdin, M.D., President and CEO of the Buck Institute for Research on Aging.
March 15-17 in Berlin, Germany
AgeX presentation: Friday, March 16 at 11:30am CET
Dr. West will discuss the prospect of using stem cell-derived cells for the treatment of age-related degenerative conditions.
The conference is being organized in part by Dr. de Grey in his capacity as Chief Science Officer of the SENS Research Foundation, which is co-sponsoring the event.
The 10th World Congress and Expo on Cell & Stem Cell Research
March 19-21 in New York City
AgeX presentation: Tuesday, March 20 at 9:00am EDT
Dr. West will deliver a presentation titled, “Induced tissue regeneration (iTR): Leveraging the unique regenerative potential of pluripotent stem cell-derived therapeutics.”
A copy of Dr. West’s presentations will be available on the AgeX website.
About AgeX Therapeutics
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), is a biotechnology company applying technology relating to cellular immortality and regenerative biology to aging and age-related diseases. The company has three initial areas of product development: pluripotent stem cell-derived brown adipocytes (AGEX-BAT1); vascular progenitors (AGEX-VASC1); and induced Tissue Regeneration (iTR). Initial planned indications for these products are Type 2 diabetes, cardiac ischemia, and tissue regeneration respectively. For more information, please visit www.agexinc.com or connect with the company on Twitter,Facebook and YouTube.
BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: cell replacement and cell/drug delivery. With its cell replacement platform, BioTime is creating new cells and tissues with its proprietary pluripotent cell technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases. BioTime’s cell/drug delivery programs are based upon its proprietary HyStem® cell and drug delivery matrix technology. HyStem® was designed to provide for the transfer, retention, engraftment and metabolic support of cellular replacement therapy. BioTime’s lead cell delivery clinical program, Renevia®, which consists of our proprietary HyStem® cell-transplantation delivery matrix combined with the patient’s own adipose progenitor cells (Fat), met its primary endpoint in an EU pivotal clinical trial for the treatment of facial lipoatrophy in HIV patients in 2017. Submission for approval of Renevia® in the EU is expected to be early 2018, with possible approval in 2018. There were no device related serious adverse events reported to date. Our lead cell replacement clinical program, OpRegen®, which is a retinal pigmented epithelium transplant therapy, is in a Phase I/IIa multicenter trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries. There were no related serious adverse events reported to date. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotime.com.
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements pertaining to product technology, clinical development, regulatory approval timelines, the success of potential cosmetic applications and potential opportunities for BioTime, Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. BioTime specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
Investor Contact for BioTime:
David Nakasone, 510-871-4188
Media Contact for AgeX:
Gotham Communications, LLC
Bill Douglass, 646-504-0890
Next Level Agency, Inc.
Mark Leonard, 847-651-9682